Cargando…
Cancer Cell Expression of Autotaxin Controls Bone Metastasis Formation in Mouse through Lysophosphatidic Acid-Dependent Activation of Osteoclasts
BACKGROUND: Bone metastases are highly frequent complications of breast cancers. Current bone metastasis treatments using powerful anti-resorbtive agents are only palliative indicating that factors independent of bone resorption control bone metastasis progression. Autotaxin (ATX/NPP2) is a secreted...
Autores principales: | David, Marion, Wannecq, Estelle, Descotes, Françoise, Jansen, Silvia, Deux, Blandine, Ribeiro, Johnny, Serre, Claire-Marie, Grès, Sandra, Bendriss-Vermare, Nathalie, Bollen, Mathieu, Saez, Simone, Aoki, Junken, Saulnier-Blache, Jean-Sébastien, Clézardin, Philippe, Peyruchaud, Olivier |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840030/ https://www.ncbi.nlm.nih.gov/pubmed/20305819 http://dx.doi.org/10.1371/journal.pone.0009741 |
Ejemplares similares
-
Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis
por: DAVID, MARION, et al.
Publicado: (2011) -
Identification of Heparin-Binding EGF-Like Growth Factor (HB-EGF) as a Biomarker for Lysophosphatidic Acid Receptor Type 1 (LPA(1)) Activation in Human Breast and Prostate Cancers
por: David, Marion, et al.
Publicado: (2014) -
Autotaxin/Lysophosphatidic Acid Axis: From Bone Biology to Bone Disorders
por: Alioli, Candide, et al.
Publicado: (2022) -
2-Carba-lysophosphatidic acid is a novel β-lysophosphatidic acid analogue with high potential for lysophosphatidic acid receptor activation and autotaxin inhibition
por: Fukasawa, Keiko, et al.
Publicado: (2021) -
Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain
por: Inoue, Makoto, et al.
Publicado: (2008)